Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining the market potential of DBV's Viaskin Patch and Aimmune’s AR-101 with an allergist in private practice

Ticker(s): AIMT, DBVT

Who's the expert?

Name: Dr Douglas McMahon - MD

Institution: Allergy and Asthma Center of Minnesota

  • Pediatric Allergist & Immunologist in private practice.
  • Sees 8 peanut allergy patients per week and is familiar with Viaskin Patch and AR-101.
  • Double Board certified in Pediatrics & Allergy, Asthma and Immunology; President of the Minnesota Allergy Society and director of Outpatient Allergy at the University of Minnesota.

Interview Questions
Q1.

Please describe your clinical background and how you currently manage your peanut allergy patients.

Added By: c_admin
Q2.

What % of your patients would you anticipate wanting to use AR101 if approved?

Added By: c_admin
Q3.

What amount of efficacy and safety from the PALISADE trial would you consider "success" - meaning, make it a preferred option for patients over Viaskin?

Added By: c_admin
Q4.

What is the likelihood of approval for each drug based upon the phase 3 data?  
Can you give an opinion as to the effectiveness of each medication?
Do you have an opinion as to whether the data generated for Viaskin is adequate or will a 2nd phase 3 be required?
Any thoughts on whether the Viaskin Patch will become more effective over time and if so at what time point will it provide adequate protection from minor inadvertent  exposure to peanuts?
Can you compare the onset of the protective effect between the two medications?
If both are approved what would the split be in utilization in your practice?
If both drugs are approved what characteristics of the patient would influence you as to which medication you would prefer the patient to start?

Added By: drsug
Q5.

Can you give us your opinion as to how the safety vs benefit balance between the two drugs?

Added By: drsug
Q6.

How does the route of administration factor into treatment decision making?  more specifically, for the pediatric audience?  

Added By: userccb2a181
Q7.

Is there still a need for a different treatment option or do these two potential entries to market cover most all patient cases you see?

Added By: userccb2a181

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.